Skip to main content
. 2017 Aug 28;4(2):233–246. doi: 10.1007/s40744-017-0076-0

Table 5.

Number of patients reporting Candida infections by type and treatment group in FUTURE-1 and 2 trials

Candida infection type FUTURE-2 FUTURE-1
300 mg 150 mg 75 mg 150 mg 75 mg
Oral candidiasis 2 3 1 2 2
Vulvovaginal candidiasis 1 3
Esophageal candidiasis 1 1
Unspecified candidiasis 1
Cutaneous candidiasis 1